BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:S241656 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of S241656\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07719348-2719@assetmemo.bio
DTSTAMP:20261121T005846Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:S241656: Phase 1/2 readout est. (NCT07719348)
DESCRIPTION:S241656\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Study t
 o Evaluate S241656 Alone or in Combination in Participants With Selected M
 yeloid Malignancies\nEstimated primary completion: 1 November 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/s241656#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07719348
URL:https://assetmemo.bio/drug/s241656#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05786924-2719@assetmemo.bio
DTSTAMP:20261121T005846Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:S241656: Phase 1/2 readout est. (NCT05786924)
DESCRIPTION:S241656\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Phase
  1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
 \nEstimated primary completion: June 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/s241656#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT05786924
URL:https://assetmemo.bio/drug/s241656#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
